Search

Displaying results 6191 - 6200 of 10000 in total
  1. Drug

    Tribulus terrestris

    go.drugbank.com/drugs/DB14358
    Investigational

    Tribulus terrestris is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  2. Drug

    Besifloxacin

    go.drugbank.com/drugs/DB06771
    Approved

    FDA approved on May 28, 2009.

  3. Drug

    Ethylmercurithiosalicylic acid

    go.drugbank.com/drugs/DB02731
    Experimental

    Ethylmercurithiosalicylic acid is a topical antiseptic used on skin and mucous membranes. It is also used as a preservative in pharmaceuticals.

  4. Drug

    TAK-475

    go.drugbank.com/drugs/DB05317
    Investigational

    TAK-475 is a "squalene synthase inhibitor", a type of cholesterol-lowering drug that has not yet been brought to market.

  5. Drug

    Meglutol

    go.drugbank.com/drugs/DB04377
    Experimental

    is the rate limiting enzyme in the biosynthesis of cholesterol. … An antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids.

  6. Drug

    Arundic acid

    go.drugbank.com/drugs/DB05343
    Investigational

    Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).

  7. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  8. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.

  9. Drug

    Aspartyl-alanyl-diketopiperazine

    go.drugbank.com/drugs/DB14940
    Investigational

    Aspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).

  10. Drug

    EU204

    go.drugbank.com/drugs/DB17438
    Investigational

    EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.